Frequently Asked Questions in Oncology: Kidney Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both foradvanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–2281.
-
Motzer RJ, Barrios CH, Kim TM, et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). Paper presented at: 2013 ASCO Annual Meeting; May 31–June 4, 2013; Chicago, Illinois. Abstract 4504. J Clin Oncol. 2013;31(suppl; abstr 4504).
-
Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962-969.
Disclosure statements are available on the authors' profiles: